Evidence map›Paper›PMID 28097100›Full record

ReviewJournal of clinical and translational hepatology2016

Hepatitis C Virus: A Review of Treatment Guidelines, Cost-effectiveness, and Access to Therapy.

Shaina M Lynch, George Y Wu

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of clinical and translational hepatology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Digital Pills with Ingestible Sensors: Patent Landscape Analysis.Pharmaceuticals (Basel, Switzerland) · 2022
    Review
  6. Article
  7. Molecular and cellular mechanisms of liver fibrosis and its regression.Nature reviews. Gastroenterology & hepatology · 2021
    Review
  8. Article
  9. Observational
  10. Article
  11. Article
  12. Article
  13. Article
  14. [A real-world study of paritaprevir/ritonavir-ombitasvir combined with dasabuvir in the treatment of genotype 1b chronic hepatitis C].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2018
    Article
  15. Hepatitis C Treatment in Patients with Drug Addiction Is Effective or Not Effective?Medical archives (Sarajevo, Bosnia and Herzegovina) · 2018
    Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Shaina M LynchDepartment of Medicine, Division of Gastroenterology-Hepatology, University of Connecticut Health Center, Hartford, USA.
George Y WuDepartment of Medicine, Division of Gastroenterology-Hepatology, University of Connecticut Health Center, Hartford, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatitis C virus (HCV) infection remains a significant medical concern in the United States and around the world. It is still one of the leading causes of chronic liver disease, and, for more than 20 years, there has been little progress in the treatment of HCV infection. The advent of direct-acting antivirals (DAAs) initiated the era of high efficacy and well-tolerated medications with high cure rates. The efficacy of these medications has prompted many professional societies around the world to update their treatment guidelines to include DAAs as first-line treatment. Guidelines by the American Association for the Study of Liver Disease/Infectious Disease Society of America, World Health Organization, Asian-Pacific Association for the Study of Liver and the European Association for the Study of Liver have all incorporated DAAs into their treatment guidelines. Despite the promising data supporting these medications, however, their cost represents a limiting factor to their use, even though studies have shown DAAs to be cost-effective. In addition to the expense of these medications and limited resources, there are many barriers preventing patients from receiving this potentially life-saving treatment. In order to overcome these barriers, these issues need to be recognized and addressed.

Indexed as

Drug therapyHCVHealth care costsHepatitis C

Identifiers

PMID28097100
PMCPMC5225151

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.